“I Was Almost in Disbelief” - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab

References

• Schafer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M. Epidemiologie der Psoriasis in Deutschland – Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung[Epidemiology of psoriasis in Germany--analysis of secondary health insurance data]. Gesundheitswesen. 2011;73(5):308–313. German. doi:10.1055/s-0030-1252022
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi:10.1136/bmj.m1590
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Patruno C, Napolitano M, Balato N, et al. Psoriasis and skin pain: instrumental and biological evaluations. Acta Derm Venereol. 2015;95(4):432–438. doi:10.2340/00015555-1965
   PubMed Web of Science ®Google Scholar
• Finlay AY, Kelly SE. Psoriasis--an index of disability. Clin Exp Dermatol. 1987;12(1):8–11. doi:10.1111/j.1365-2230.1987.tb01844.x
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi:10.1056/NEJMra0804595
   PubMed Web of Science ®Google Scholar
• Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi:10.3389/fimmu.2018.00579
   PubMed Web of Science ®Google Scholar
• Hölsken S, Krefting F, Schedlowski M, Sondermann W. Common fundamentals of psoriasis and depression. Acta Derm Venereol. 2021;101(11):adv00609. doi:10.2340/actadv.v101.565
   PubMedGoogle Scholar
• Tribo MJ, Turroja M, Castano-Vinyals G, et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Derm Venereol. 2019;99(4):417–422. doi:10.2340/00015555-3114
   PubMed Web of Science ®Google Scholar
• Malhotra SK, Mehta V. Role of stressful life events in induction or exacerbation of psoriasis and chronic urticaria. Indian J Dermatol Venereol Leprol. 2008;74(6):594–599. doi:10.4103/0378-6323.45100
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18). doi:10.3390/ijms20184347
   Web of Science ®Google Scholar
• Mrowietz U, Dieckmann T, Gerdes S, Szymczak S, von Spreckelsen R, Körber A. ActiPso: definition of activity types for psoriatic disease: a novel marker for an advanced disease classification. J Eur Acad Dermatol Venereol. 2021;35(10):2027–2033. doi:10.1111/jdv.17434
   PubMed Web of Science ®Google Scholar
• Nast A, Altenburg A, Augustin M, et al. German S3-guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934. doi:10.1111/ddg.14508
   Web of Science ®Google Scholar
• Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6). doi:10.3390/ijms20061475
   Web of Science ®Google Scholar
• Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. J Cutan Med Surg. 2009;13(Suppl 2):S67–76. doi:10.2310/7750.2009.00023
   PubMedGoogle Scholar
• Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 study group. Br J Dermatol. 1998;139(1):88–95. doi:10.1046/j.1365-2133.1998.02319.x
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi:10.1001/jamadermatol.2019.4029
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Efficacy and Safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5). doi:10.3390/ijms21051690
   Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(5):355–362. doi:10.1080/14740338.2023.2218086
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled Phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–421. doi:10.1111/bjd.12110
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two Phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A. Novel therapeutic approaches and targets for treatment of psoriasis. Curr Pharm Biotechnol. 2021;22(1):7–31. doi:10.2174/1389201021666200629150231
   PubMed Web of Science ®Google Scholar
• Colloca L. The placebo effect in pain therapies. Ann Rev Pharmacol Toxicol. 2019;59:191–211. doi:10.1146/annurev-pharmtox-010818-021542
   PubMed Web of Science ®Google Scholar
• Schedlowski M, Enck P, Rief W, Bingel U. Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev. 2015;67(3):697–730. doi:10.1124/pr.114.009423
   PubMed Web of Science ®Google Scholar
• Sondermann W, Reinboldt-Jockenhofer F, Dissemond J, Pfaar O, Bingel U, Schedlowski M. Effects of patients’ expectation in dermatology: evidence from experimental and clinical placebo studies and implications for dermatologic practice and research. Dermatology. 2021;1–15. doi:10.1159/000513445
   Web of Science ®Google Scholar
• Sonthalia S, Sahaya K, Arora R, et al. Nocebo effect in Dermatology. Indian J Dermatol Venereol Leprol. 2015;81(3):242–250. doi:10.4103/0378-6323.155573
   PubMed Web of Science ®Google Scholar
• Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med. 2020;382(6):554–561. doi:10.1056/NEJMra1907805
   PubMed Web of Science ®Google Scholar
• Schafer I, Oltrogge JH, Nestoriuc Y, et al. Expectations and prior experiences associated with adverse effects of COVID-19 vaccination. JAMA Network Open. 2023;6(3):e234732. doi:10.1001/jamanetworkopen.2023.4732
   PubMed Web of Science ®Google Scholar
• Wensing M, Elwyn G. Methods for incorporating patients’ views in health care. BMJ. 2003;326(7394):877–879. doi:10.1136/bmj.326.7394.877
   PubMedGoogle Scholar
• Holsken S, Krefting F, Schedlowski M, Sondermann W. Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial. BMJ Open. 2021;11(9):e047099. doi:10.1136/bmjopen-2020-047099
   PubMedGoogle Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi:10.1093/intqhc/mzm042
   PubMed Web of Science ®Google Scholar
• O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245–1251. doi:10.1097/ACM.0000000000000388
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Cosentyx: EPAR - Product Information. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf. Accessed June 14, 2024.
   Google Scholar
• Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–1907. doi:10.1007/s11135-017-0574-8
   PubMed Web of Science ®Google Scholar
• maxqda.com. MAXQDA, software for qualitative data analysis; 2022.
   Google Scholar
• Kuckartz U. Qualitative Inhaltsanalyse: Methoden, Praxis, Computerunterstützung. 4. überarbeitete Auflage [Qualitative content analysis: methods, practice, digital applications, 4th ed.] [Book in German]. Beltz Verlagsgruppe; 2018.
   Google Scholar
• Sumpton D, Kelly A, Tunnicliffe DJ, et al. Patients’ perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. Arthritis Care Res. 2020;72(5):711–722. doi:10.1002/acr.23896
   Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
   PubMed Web of Science ®Google Scholar
• Miniszewska J, Juczynski Z, Ograczyk A, Zalewska A. Health-related quality of life in psoriasis: important role of personal resources. Acta Derm Venereol. 2013;93(5):551–556. doi:10.2340/00015555-1530
   PubMed Web of Science ®Google Scholar
• Larsen MH, Krogstad AL, Aas E, Moum T, Wahl AK. A telephone-based motivational interviewing intervention has positive effects on psoriasis severity and self-management: a randomized controlled trial. Br J Dermatol. 2014;171(6):1458–1469. doi:10.1111/bjd.13363
   PubMed Web of Science ®Google Scholar
• Eissing L, Radtke MA, Zander N, Augustin M. Barriers to guideline-compliant psoriasis care: analyses and concepts. J Eur Acad Dermatol Venereol. 2016;30(4):569–575. doi:10.1111/jdv.13452
   PubMed Web of Science ®Google Scholar
• Augustin M, Alvaro-Gracia JM, Bagot M, et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol. 2012;26(Suppl 4):1–16. doi:10.1111/j.1468-3083.2012.04576.x
   PubMed Web of Science ®Google Scholar
• Nestoriuc Y, von Blanckenburg P, Schuricht F, et al. Is it best to expect the worst? Influence of patients’ side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Ann Oncol. 2016;27(10):1909–1915. doi:10.1093/annonc/mdw266
   PubMed Web of Science ®Google Scholar
• Michnevich T, Pan Y, Hendi A, Oechsle K, Stein A, Nestoriuc Y. Preventing adverse events of chemotherapy for gastrointestinal cancer by educating patients about the nocebo effect: a randomized-controlled trial. BMC Cancer. 2022;22(1):1008. doi:10.1186/s12885-022-10089-2
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• PsoNet e.V. FfrPiD. Globaler Bericht zur Schuppenflechte. Deutsche Übersetzung des Global Report on Psoriasis”; 2016.
   Google Scholar
• Lawson A, Tan AC, Naylor J, Harris IA. Is retrospective assessment of health-related quality of life valid? BMC Musculoskelet Disord. 2020;21(1):415. doi:10.1186/s12891-020-03434-8
   PubMed Web of Science ®Google Scholar